This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Bai JPF, Hsu CW (2018) Drug repurposing for Ebola virus disease: principles of consideration and the animal rule. J Pharm Sci 108:798–806
Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Dong L, Garza NL, Donnelly G, Cazares LH, Nuss J, Soloveva V, Koistinen KA, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK (2017) Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir Res 151:97–104
Brauburger K, Hume AJ, Muhlberger E, Olejnik J (2012) Forty-five years of Marburg virus research. Viruses 4:1878–1927
Cross RW, Mire CE, Feldmann H, Geisbert TW (2018) Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov 17:413–434
Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr (2015) Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160:893–903
Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr (2016) Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebola virus infection. Cell 164:392–405
Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A (2014) Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3:e84
Leffel EK, Reed DS (2004) Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2:186–191
Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ (2013) A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS ONE 8:e60579
Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 1:317–326
Marzi A, Banadyga L, Haddock E, Thomas T, Shen K, Horne EJ, Scott DP, Feldmann H, Ebihara H (2016) A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci Rep 6:39214
Wang J, Cheng H, Ratia K, Varhegyi E, Hendrickson WG, Li J, Rong L (2014) A comparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses. J Biomol Screen 19:100–107
Zhang L, Li Q, Liu Q, Huang W, Nie J, Wang Y (2017) A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother 13:1811–1817
We are grateful to Zongge Zhao and Lihua Xie from the Institute for Reference Standards and Standardization, National Institutes for Food and Drug Control, for providing the compounds. This work was supported by the National Key Research and Development Plan of China (Grant No. 2016YFC1200904). The funding bodies had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
The authors report no conflicts of interest.
Animal and Human Rights Statement
All institutional and national guidelines for the care and use of laboratory animals were followed.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Zhang, L., Lei, S., Xie, H. et al. Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs. Virol. Sin. 35, 235–239 (2020). https://doi.org/10.1007/s12250-019-00184-3